Our Tenants

We have been home to many life science start-ups

 

Project "Treatment of Thromboembolic Pulmonary Hypertension Using JAK Inhibitors" by the Almazov National Medical Research Center, Saint Petersburg - Participant CoLaborator Russia

The project develops a groundbreaking new treatment for thromboembolic pulmonary hypertension using JAK inhibitors, currently applied in cancer therapy. The authors have designed a qualitative model of thromboembolic pulmonary hypertension which allows for efficient selection of the most viable molecules at early stages and maximize the chance of success for the molecules in clinical trials, thus actively implementing the approach from translational medicine.

Aronora, Inc. - Tenant CoLaborator San Francisco

Aronora is developing products intended to be used in difficult-to-treat, severe, rapidly progressing, or catastrophic thrombotic blood clotting diseases, including suspected or verified stroke, heart attack, pulmonary embolism, severe infections, and others. Building on the company’s ground-breaking approaches to superior drug safety, Aronora’s product candidates have the potential to become first-in-class medical emergency therapeutics to treat acute thrombotic diseases.

BioGraph 55 - Tenant CoLaborator San Francisco

BioGraph 55 is an immuno-oncology target discovery and drug development company that uses advanced imaging analytics and machine learning to capture clinically relevant content from the tumor microenvironment. We leverage a proprietary spatial ‘omics’ platform called SPARTA to capture unique biological information that reflects clinical disease and is druggable. BioGraph 55 is discovering and developing therapies that target the underlying cellular interactomes that give rise to suppressive functional programs in tumors.

Biome Makers - Tenant CoLaborator West Sacramento

Biome Makers is a biotech company born in Silicon Valley specialized in the identification and understanding of the microbiome. We use DNA Sequencing technologies and proprietary Intelligent Computing systems to ease detailed information and recommendations that allow customers improve their agricultural production and the quality of their products. Biome Makers is committed to the environment and the future of our planet through the management of a sustainable agriculture that allows adequate yields and promises worldwide food security. The first application of the technology is WineSeq, a microbiome based solution that helps to improve vineyard management providing an individualized diagnosis of vineyard health status and value.

Cairn Biosciences - Tenant CoLaborator San Francisco

Cairn Biosciences is developing next-generation therapeutics that address significant challenges in the treatment of serious diseases. Cairn’s drug discovery engine addresses the profound unmet need for new tools to decipher cellular complexity and enable scalable discovery of groundbreaking therapies. Our proprietary approach enables us to monitor multiple dynamic facets of previously inaccessible biology in live cells and fast-track the discovery of a pipeline of drugs for a wide range of indications with an initial focus on cancer.

Casebia Therapeutics - Tenant CoLaborator San Francisco

Casebia Therapeutics, a 50-50 joint venture between CRISPR Therapeutics and Bayer, was created to accelerate the field of gene editing therapeutics today, and for the long haul. Drawing on CRISPR/Cas9 technology and expertise from CRISPR Therapeutics and the distinctive disease know-how and protein engineering capabilities of Bayer, we are working to redefine what’s possible for patients with a wide range of inherited diseases.

DNALite Therapeutics - Tenant CoLaborator San Francisco

DNALite Therapeutics is delivering gene therapies to treat diseases of epithelial tissues. Our first drug is for an orphan disease, Familial Adenomatous Polyposis, that results in a 100% chance of colorectal cancer by the age of 39 which results in patients having their entire colon and rectum removed in their teens. DNALite is replacing these surgeries using gene therapy via our proprietary technology that allows us to deliver biologics to the cells that drive colon cancer. We aim to create first-in-class gene therapy drugs for diseases of the intestinal, respiratory and cervical linings that will treat them at the source rather than addressing only the symptoms.

Epigeneron, Inc. - Tenant CoLaborator Kobe

Epigeneron is a bio-venture launched from Osaka University and the first tenant at CoLaborator Kobe. This company strives to develop practical technologies for drug discovery target identification, and therapies for intractable diseases such as cancer and central nervous system diseases caused by abnormal gene expression.

Eternygen - Tenant CoLaborator Berlin

Eternygen is a Berlin based start-up founded in June 2012 focusing on research and development of innovative drugs using a network of renowned scientists and contract research organizations. The main focus of Eternygen´s development and core competences of its founders are research and development of new drugs for dietary-related metabolic diseases with dramatically increasing prevalences in the last decades. Eternygen´s research addresses the sodium coupled citrate transporter NaCT which is a key regulator of lipid metabolism involved in the pathogenesis of fatty liver, diabetes and obesity.

Explora BioLabs - Tenant CoLaborator San Francisco

Explora BioLabs, an AAALAC-accredited preclinical CRO, provides full-service pharmacology housing and procedure facilities, as well as technical support services, to Bayer and to the CoLaborator’s biotech tenants and neighbors. Explora operates additional pharmacology facilities in South San Francisco and San Diego, and also performs contract research in the areas of oncology, wound healing, metabolic diseases, pharmacokinetics, and toxicology.

Fair Access Medicines - Tenant CoLaborator San Francisco

Fair Access Medicines is a California based 501(c)(3) nonprofit organization whose mission is to supply medicines to patients with unmet medical needs. Our initial effort is to provide insulin to patients who are uninsured or underinsured in the United States but eventually to expand our effort to worldwide distribution. We are experienced former pharmaceutical development and manufacturing scientists who are dedicated to providing affordable medications to patients. Our plan is to develop a process for insulin manufacture suitable for large scale manufacturing and FDA approval. Our intention is to sell our FDA approved product at the lowest possible price.

Feral GmbH - Tenant CoLaborator Berlin

Feral is a Berlin based biotech start-up, using science and technology to make natural contraception effective and convenient. Our vision is enable women to make informed decisions about their fertility, sexuality and general female health by provide simple and smart solutions. Our first product is a hand held device that uses biochemical and optical sensor for daily hormone monitoring and transmits data wirelessly to a connected app.

INVICOL - Tenant CoLaborator Berlin

INVICOL GmbH, headquartered in Berlin-Wedding, is a young start-up founded in January 2016. We are active in the field of molecular diagnostics of peripheral blood and other body fluids. Circulating blood and body fluids transport therapy-relevant biomarkers and other metabolic products, which need to be identified and analysed. The data obtained are of great value in the field of personalized medicine. Currently INVICOL is focused on detecting free nucleic acids and subcellular compartments such as exosomes. These new approaches to nucleic acid-based diagnostics will become increasingly important in human medicine. The screening can be extended, for example, to include the identification of rare cells from body fluids. INVICOL also has expertise in the field of immuno-screening, i.e. the identification of clinically relevant antibodies and antigens.

Liquid Genomics - Tenant CoLaborator Berlin

Liquid Genomics, Inc. was founded in 2013 in Torrance, California, USA. Liquid Genomics’ CEO is Kathleen Danenberg. The company is focused on transitioning cancer diagnostics from tissue to non-invasive blood-based tests for cancer drug targets. Cancer is a dynamic disease that cannot be effectively treated using a static test. Real time monitoring of drug targets is essential to making informed treatment decisions and adjustments to a patient’s therapy while there is still time to treat. Liquid biopsies allow the physician to continually attack the ever-evolving tumor over the course of the disease with the most effective chemotherapies. Liquid Genomics provides this testing in a rapid, cost-effective manner during clinical trials and beyond.

Mantra Bio - Tenant CoLaborator San Francisco

Mantra Bio is a biotechnology company focused on developing effective and safe exosome-based therapeutics to combat intractable diseases. Mantra Bio is the creator of REVEAL, the world’s first exosome intelligence platform leveraging deep data and lab automation to discover novel drugs.

Myoridge Co. Ltd. - Tenant CoLaborator Kobe

Myoridge is a bio-venture from Kyoto University. Myoridge endeavors to support the solution of challenges in new drug development by providing drug discovery support tools that lower cost through the use of iPS cell-derived cardiomyocytes based on a protein-free method of inducing myocardial differentiation.

Nalo Therapeutics - Tenant CoLaborator San Francisco

Nalo Therapeutics was formed in 2017 to develop small molecule based pharmaceutical products around recently discovered cancer biology for the treatment of hematological and solid tumors. Nalo is composed of a team of senior biopharmaceutical leaders, each with decades of successful pharmaceutical development experience in the areas of discovery, pharmacology, medicinal chemistry, DMPK, formulation, toxicology and clinical development in oncology and other disease areas. Nalo is headquartered in Mission Bay with local and global collaborators.

NMI TT Pharmaservices - Tenant CoLaborator Berlin

NMI TT Pharmaservices is a Contract Research Organization dedicated to provide integrated experts services to the pharmaceutical industry, as well as to biotechnical and medical technology companies. Our business is focused on high quality products and services and R&D support in the fields of preclinical drug discovery and profiling as well as in safety pharmacology. We are committed to quality, accuracy and efficiency. A distinct customer liaison and support by our project managers ensures a close interaction with our clients to accelerate our customer´s project development.

At our new site at the CoLaborator we will install a novel proprietary technology that will help to bring our expertise to partners in pharma and biotech. Multiplexed protein expression and analysis of cellular signal transduction pathways is performed on a highly reliable Western-Blot like assay system to support drug discovery and biomarker screening. NMI TT, founded in 2002, is a spin-off of the Natural and Medical Sciences Institute (NMI) at the University of Tübingen.

ProLynx LLC - Tenant CoLaborator San Francisco

ProLynx LLC, founded in 2009, is developing a technology platform that overcomes major limitations of releasable linkers currently used in drug conjugation. The technology uses sets of novel linkers that cleave at different, pre-programmed rates to allow the controlled, predictable and sustained release of native, active drugs – peptides, proteins and small molecules – from circulating and fixed macromolecular conjugates.

Provitro - Tenant CoLaborator Berlin

Provitro AG is an innovative molecular-pathological service provider for preclinical and clinical research in pharmacology and biotechnology. The company's principal business area is based on a well-stocked tissue bank and close scientific cooperation with pathologists of Charité University Hospital Berlin. Normal and diseased tissue samples can be provided as single slide or customized Tissue Microarray block for biomarker analyzes.  Its competence is not limited to target validation by means of immunohistochemistry and In-situ-hybridization but includes, as well, the development of protocols for both manual and automated IHC and ISH staining. Pathological result evaluation completes this field of service. Furthermore, normal and diseased tissue samples can be provided as single slides or customized tissue microarrays for in-house biomarker analyzes. 

The second line of business is based on its proprietary know-how in cell biology; it comprises a broad spectrum of cell culture products with a focus on a large variety of human primary cell types and corresponding culture media. Provitro as a certified company provides its customers not only with high-quality products and state-of-the-art services but also with individual solutions for their specific requests. In 2018, provitro participated in Bayer’s sustainability initiative, and the evaluation result places the company among the top 30 % performers.

Singular BIO Inc. - Tenant CoLaborator San Francisco

Singular Bio, Inc. develops platforms for diagnostic testing in personalized medicine. The company was incorporated in 2012 and is based in San Francisco, California.

Project "Development of Aldosterone Synthase Inhibitor – First-Ever Agent in Treatment of Cardiometabolic Diseases" by Target Medicals - Participant CoLaborator Russia

The main focus of the project is the search of new regulation mechanisms of the renin–angiotensin–aldosterone system (RAAS) through the development of viable selective aldosterone synthase inhibitor. Solving this problem will allow to apply new approaches in the treatment of chronic kidney and heart failure. The agent the authors are developing is one of a kind and has every chance to become the first in its class.

Treamid Therapeutics - Tenant CoLaborator Berlin

Treamid Therapeutics develops innovative treatments in areas of high unmet medical needs. Our portfolio includes potential new treatments for several endocrine and respiratory diseases. Both areas threaten health gains made during the past century and are one of the most important levers for improving health care in the 21st century. Treamid Therapeutics is a Berlin based start-up founded in 2017 by serial life sciences entrepreneurs.

Project "CAR-NK Cells As Platform for Universal Cancer Therapy" by the Institute of Molecular and Cellular Biology, Siberian Branch of the RAS, Novosibirsk - Participant CoLaborator Russia

The project focuses on the development of one of the most promising approaches in cancer therapy: chimeric antigen receptor (CAR) cell-based therapy. The products existing on the market are based on autologous (taken from the patient) cells, which drastically complicates the procedure. Besides, current field of application of CAR therapy is limited to oncohematology, while in solid tumors this therapy is a lot less efficient. The project suggests that the use of modified allogenic CAR-NK cells instead of autologous CAR-T cells will solve the problem of high cost, while further modifications will allow to increase their efficiency for a wider range of cancerous diseases.

Verge Genomics - Tenant CoLaborator San Francisco

Verge Genomics is a next-generation drug discovery company that is using human genomics to accelerate drug discovery. The Verge team is 13 people including 11 Ph.D.s with expertise in machine learning, neuroscience, drug development, applied math, biophysics, and statistics from UCLA, Stanford, Oxford, and UCSF. The company has developed a proprietary platform to predict and test new therapeutics for neurodegenerative diseases.

Xcell Biosciences - Tenant CoLaborator San Francisco

Xcell Biosciences is a San Francisco-based life science company dedicated to bringing an innovative primary cell culture solution to the market to support research, drug discovery, and personalized patient information. Xcell’s mission is to democratize the culture of primary cells from patient blood for all research labs, regardless of size and experience, through its bench-top primary cell bioreactor, reagent kits, and standardized protocols. The technology delivers simple culture of primary cell types from patient blood, including circulating tumor cells, stem cells, and immune cells. This patient-centric technology enables direct disease insights without a biopsy, complementing existing cell lines and mouse models used for clinical research and drug discovery.

 

Read what our tenants say about the CoLaborator